US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Allogene Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Planned CEO Succession
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO CLLS
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
< Previous 1 2 3 4 Next >